Aristo Bio-Tech & Lifescience Ltd (ARISTO) — shareholding pattern, promoter holding, financials and share price
About Aristo Bio-Tech & Lifescience Ltd (ARISTO)
Aristo Bio-Tech & Lifescience Ltd operates in the Industrial Products industry, within the Capital Goods sector. It trades on the NSE as ARISTO and on the BSE under scrip code 76744. Its ISIN is INE082101010.
Incorporated in 2005, Aristo Bio-Tech and Lifescience Ltd manufactures and supplies pesticides and agrochemicals [1]
Aristo Bio-Tech & Lifescience Limited is an agrochemical company focused on manufacturing and supplying pesticides and agrochemicals like insecticides, herbicides, fungicides, and plant growth regulators.
The company has expanded its operations beyond its primary state to Punjab and Uttar Pradesh, demonstrating a growing geographical reach.
Listed peers in Industrial Products: Siddhi Cotspin Ltd, Shantai Industries Ltd, Milton Industries Ltd, Greenleaf Envirotech Ltd, Paramount Speciality Forgings Ltd, Naman Industries Proxima Limited.
Valuation & Returns
At ₹110 a share, Aristo Bio-Tech & Lifescience Ltd (ARISTO) was valued at a price-to-earnings ratio of 9.02x against an industry P/E of 48.01x and a price-to-book of 1.45x on a book value of ₹65.39 per share. Solomo computes return on equity of 16.14% and return on capital employed of 17% from filed results.
- P/E
- 9.02x
- Industry P/E
- 48.01x
- P/B
- 1.45x
- EPS (TTM)
- ₹5.97
- Book value / share
- ₹65.39
- ROE
- 16.14%
- ROCE
- 17%
- ROA
- 4.63%
- Debt / equity
- 0.8x
- Dividend yield
- 0.63%
- EBITDA margin
- 4.54%
- 52-week range
- ₹74.3 – ₹140
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Aristo Bio-Tech & Lifescience Ltd (ARISTO) reported revenue of ₹364 crore, net profit of ₹7 crore and earnings per share of ₹10.55. That compares with revenue of ₹318 crore and net profit of ₹4 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹107 crore and net profit ₹3 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 166 | 218 | 245 | 318 | 364 |
| Net profit (₹ cr) | 1 | 4 | 4 | 4 | 7 |
| EPS (₹) | 2.14 | 5.23 | 5.73 | 5.96 | 10.55 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 21.03% | 6.20% | 24.27% | 29.75% |
| Profit growth | 29.46% | 32.17% | 41.51% | 4.10% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 73.42% of Aristo Bio-Tech & Lifescience Ltd (ARISTO). Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2023.
Largest disclosed public shareholders in Mar 2026: Falguni Shreyash Shah 3.13%, Kabra Sunil Murlimanohar 2.35%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 73.42% | - | - | - | - |
| Sep 2025 | 73.42% | - | - | - | - |
| Mar 2025 | 73.42% | - | - | - | - |
| Sep 2024 | 73.37% | - | - | - | - |
| Mar 2024 | 73.37% | - | - | - | - |
| Sep 2023 | 73.37% | - | - | - | - |
| Mar 2023 | 73.37% | - | - | - | - |